Image

Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy

Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy

Recruiting
18-65 years
All
Phase N/A

Powered by AI

Overview

The study hypothesis is that liver transplantation after selective internal radiation therapy (SIRT) and chemotherapy would improve 3-year overall survival in patients with locally advanced (unresectable but non-metastatic) intrahepatic cholangiocarcinoma.

It is planned to include 36 patients with locally advanced intrahepatic cholangiocarcinoma, not eligible for initial surgery and without metastases. Participants will be recruited from care facilities in France.

Description

The hypothesis of the study is that liver transplantation after selective internal radiation therapy (SIRT) and chemotherapy would improve the overall 3-year survival of patients with locally advanced intrahepatic cholangiocarcinoma (unresectable but not metastatic).

All patients over 18 and under 65 years of age with histologically evidence, pauci-nodular (N≤5), locally advanced Intrahepatic cholangiocarcinoma (IHC) without extrahepatic involvement, considered technically unresectable by a panel of experts, eligible for treatment with SIRT, gemcitabine + cisplatin chemotherapy and Liver Transplant (LT).

Following treatment with SIRT + chemotherapy, tumor response or absence of tumor progression will be verified by a morphological workup combining CT-imaging, hepatic MRI and PET-CT.

After exploratory surgery to rule out any contraindications for LT, the patient will be list , with a minimum waiting of 3-month Follow-up will include assesment of Liver graft function, efficiency and tolerance of immunosuppressive therapy.

Eligibility

Inclusion Criteria:

  • Patient aged 18 to 65
  • With histologically documented intrahepatic cholangiocarcinoma (primary diagnosis):
    • Uni or pauci nodular (≤ 5 lesions (all lesions are counted, even those less than 1 cm))
    • Without extrahepatic or lymph node involvement
    • Technically unresectable R0 according to an expert panel
  • Tumor target \> 2 cm
  • WHO 0-1
  • free and informed consent signed
  • highly effective contraception for men and women of childbearing age during study participation up to 2 years post TH

Exclusion Criteria:

  • Extrahepatic, vesicular or perihilar cholangiocarcinoma
  • Tumor infiltration of more than 50% of the liver
  • Mixed cholangiocarcinoma, hepatocellular carcinoma, fibrolamellar carcinoma
  • Previous treatment for CCI
  • Cirrhosis ≥ Child B7
  • Chronic alcoholism
  • Uncontrolled chronic active infections (patients with HBV, HCV or HDV infections may be included if infections are controlled)
  • Stage III A, IIIB, IV and V chronic renal failure (glomerular filtration rate 59 ml/min)
  • Contraindications to liver transplant
    • Severe untreatable conditions
    • Recent history (less than 5 years) of cancer
    • severe comorbidities
    • Psychiatric or psychological disorders
  • Pregnant or breast-feeding women
  • Patient under guardianship
  • Not affiliated to a Health care system
  • Participating in another interventional study or within the exclusion period of a previous study involving the human body

Study details
    Intrahepatic Cholangiocarcinoma
    Locally Advanced Intrahepatic Cholangiocarcinoma

NCT06910722

Assistance Publique - Hôpitaux de Paris

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.